Ligand Pharmaceuticals CEO John Higgins' 2021 pay jumps 64% to $9.6M
Ligand Pharmaceuticals reports 2021 executive compensation
By ExecPay News
Published: April 22, 2022
Ligand Pharmaceuticals reported fiscal year 2021 executive compensation information on April 22, 2022.
In 2021, four executives at Ligand Pharmaceuticals received on average a compensation package of $6.1M, a 71% increase compared to previous year.
Average pay of disclosed executives at Ligand Pharmaceuticals
John L. Higgins, Chief Executive Officer, received $9.6M in total, which increased by 64% compared to 2020. 63% of Higgins' compensation, or $6M, was in stock awards. Higgins also received $522K in non-equity incentive plan, $2.3M in option awards, $697K in salary, as well as $7.4K in other compensation.
Matthew Korenberg, Chief Financial Officer, received a compensation package of $6.7M, which increased by 116% compared to previous year. 73% of the compensation package, or $4.9M, was in stock awards.
Matthew W. Foehr, Chief Operating Officer, earned $5.3M in 2021, a 52% increase compared to previous year.
Charles S. Berkman, General Counsel, received $3M in 2021, which increases by 53% compared to 2020.
Related executives
You may also like
Source: SEC filing on April 22, 2022.